Advertisement

Chronic Myelogenous Leukemia in Blastic Phase: A Model of Heterogeneity and Resistance in Acute Leukemia

  • H. M. Kantarjian
  • M. Talpaz
  • M. Wetzler
  • S. O’Brien
  • E. Estey
  • W. Plunkett
  • W. Zhang
  • M. J. Keating
  • A. Deisseroth
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

The heterogeneity and resistance of chronic myelogenous leukemia in blastic phase (CML-BP) are attributed to: (1) the involvement of the earliest progenitor cell by the disease ptocess and (2) the acquisition of multiple mutational events during the evolution from the chronic to the blastic phase.

Keywords

Chronic Myelogenous Leukemia Blast Crisis Acute Lymphoid Leukemia Chronic Myelomonocytic Leukemia Chronic Granulocytic Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ (1987) Chronic myelogenous leukemia in blast crisis: an analysis of 242 patients. Am J Med 83: 445–454PubMedCrossRefGoogle Scholar
  2. 2.
    Collins SJ (1986) Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Amplification of rearranged c-abl oncogenes in CML blast crisis. J Clin Invest 78: 1392–1396PubMedCrossRefGoogle Scholar
  3. 3.
    Andrews DF III, Collins SJ (1987) Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis. Leukemia 1: 718–724PubMedGoogle Scholar
  4. 4.
    Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, Manor Y, Cohen A, Rotter V (1989) Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood 74: 2318–2324PubMedGoogle Scholar
  5. 5.
    Bar-Eli M, Ahuja H, Foti A, Sun X-Z, Cline MJ (1989) The P53 gene in blast crisis, other hematologic malignancies and solid tumors. Blood 74 [Suppl 1] 465Google Scholar
  6. 6.
    Mashal R, Shtalrid M, Talpaz M, Kantarjian H, Smith L, Beran M, Cork A, Trujillo J, Gutterman J, Deisseroth A (1990) Rearrangement and expression of p.53 in the chronic phase and blastic crisis of chronic myelogenous leukemia. Blood 75: 180–189PubMedGoogle Scholar
  7. 7.
    Zhang W, Del Giglio A, Kantarjian H,Talpaz M, Deisseroth A (1991) Nuclear p53 protein increases from normal levels inc hronic phase CML to high levels in peripheral blood cells of most blast crisis CML patients. Soc Clin Oncol (to be published)Google Scholar
  8. 8.
    Wetzler M, Kurzrock R, Estrov Z, Shtalrid M, Troutman K, Kantarjian H, Gutterman JU, Talpaz M (1990) Constitutive expression of interleukin-1 beta correlates with interfe-ron-alpha resistance in chronic myelogenous leukemia. Blood 76 [Suppl 1]: 335aGoogle Scholar
  9. 9.
    Everson MP, Brown CB, Lilly MB (1980) Interleukin-6 and granulocyte-macrophage colony-stimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells. Blood 74: 1472–1476Google Scholar
  10. 10.
    Gualtieri RJ, Emanuel PD, Zuckerman KS, Martin G, Clark SC,Shadduck RK, Dracker RA, Akabutu J, Nitschke R, Hetherington ML, Dickerman JD, Hakami N, Castleberry RP (1989) Granulocyte-macrophage colony-stimulating factor is an endogenous regulator of cell proliferation in juvenile chronic myelogenous leukemia. Blood 74: 2360–2367Google Scholar
  11. 11.
    LeMaistre A, Lee MS, Talpaz M, Kantarjian HM, Freireich EJ, Deisseroth AB, Trujillo JM, Stass SA (1980) RAS oncogene mutations are rare late stage events in chronic myelogenous leukemia. Blood 73: 889Google Scholar
  12. 12.
    Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, Talpaz M, Cork A, Freireich EJ, Trujillo JM, Lee M-S, Stass SA (1990) RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood 76: 1214–1219PubMedGoogle Scholar
  13. 13.
    Padua RA, Carter G, Hughes D, Gow J, Farr C, Oscier D, McCormick F, Jacobs A (1988) RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia 2: 503–510PubMedGoogle Scholar
  14. 14.
    Thomas ED, Clift RA, Fefer A, Appelbaum FR et al. (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104: 155–163PubMedGoogle Scholar
  15. 15.
    Goldman JM, Apperley JF, Jones L, Marcus R et al. (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314: 202–207PubMedCrossRefGoogle Scholar
  16. 16.
    Haines LD, Goldman JM, Worsley AM, McCarthy DM et al. (1984) Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probably pro-longation of survival for some patients. Br J Haematol 58: 711–721PubMedCrossRefGoogle Scholar
  17. 17.
    Reiffers J, Gorin N, Michallet M, Maraninchi D, Herve P (1986) Autografting for chronic granulocytic leukemia in transformation. J Natl Cancer Inst 76: 1307–1310PubMedGoogle Scholar
  18. 18.
    Iacoboni SJ, Plunkett WK, Kantarjian H, Estey E, Keating MJ, McCredie KB, Freireich EJ (1986) High dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 4: 1079–1088PubMedGoogle Scholar
  19. 19.
    Kantarjian H, Walters R, Keating M, Talpaz M, Andersson B, Beran M, Mcredie K, Freireich E (1988) Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 62: 672–676PubMedCrossRefGoogle Scholar
  20. 20.
    DiRaimondo F, Milone G, Guglielmo P, Cacciola E, Giustoliso R (1985) Treatment of CML blast crisis with low dose ara-C. Br J Haematol 60: 773–774PubMedCrossRefGoogle Scholar
  21. 21.
    Koller CA, Miller DM (1986) Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. N Engl J Med 315 (23): 1433–1438PubMedCrossRefGoogle Scholar
  22. 22.
    Koller C, Keating M, Walters R et al. (1988) Mithramycin and hydroxyurea in chronic myelogenous leukemia and other hematologic malignancies. Blood 72 [Suppl 1]: 209aGoogle Scholar
  23. 23.
    Trumper L, Lie JVD, Goudsmit R, Ho AD, Hunstein W (1988) Therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea: a retrospective analysis. 22nd Congress of ISH, Milan, SYM-TU-6–6, 1988Google Scholar
  24. 24.
    Antimi M, Poeta GD, Cianciulli P, Scimo MT et al. (1988) Plicamycin and hydroxyurea in the treatment of blast phase and accelerated phase of the Ph’ chronic myelogenous leukemia. 22nd Congress of ISH, Milan, OPTU-6–6, 1988Google Scholar
  25. 25.
    Tricot G, Jayaram HN,Weber G, Hoffman R (1990) Tiazofurin: biological effects and clinical uses. Int J Cell Cloning 8: 161–170Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • H. M. Kantarjian
    • 1
  • M. Talpaz
    • 2
  • M. Wetzler
    • 2
  • S. O’Brien
    • 1
  • E. Estey
    • 1
  • W. Plunkett
    • 1
  • W. Zhang
    • 1
  • M. J. Keating
    • 1
  • A. Deisseroth
    • 1
  1. 1.Departments of HematologyMD Anderson Cancer CenterHoustonUSA
  2. 2.Clinical Immunology and Biological TherapyMD Anderson Cancer CenterHoustonUSA

Personalised recommendations